Get the Stockscreener App
9.11
5.93%
0.51
Monte Rosa Therapeutics Inc Stock (GLUE) Forecast
The Monte Rosa Therapeutics Inc (GLUE) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $6.5869, representing a -27.70% decrease from the current price of $9.11. The highest analyst price target is $7.4587, and the lowest is $5.7152.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GLUE Price Target
Average 6.0486
(-33.60% Downside)
Is Monte Rosa Therapeutics Inc (GLUE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 61.60 | Neutral |
| STOCH(9,6) | 52.76 | Neutral |
| STOCHRSI(14) | 51.47 | Neutral |
| MACD(12,26) | 0.4309 | Sell |
| ADX(14) | 36.75 | Buy |
| William %R | -43.00 | Neutral |
| CCI(14) | 44.61 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
8.344
Buy
|
8.5709
Buy
|
| MA20 |
8.7525
Buy
|
8.3177
Buy
|
| MA50 |
6.926
Buy
|
7.3651
Buy
|
| MA100 |
6.007
Buy
|
6.5207
Buy
|
| MA200 |
5.7119
Buy
|
5.8845
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, GLUE could be considered a Strong Buy, with 17 technical analysis indicators signaling 11 Buy signals, 1 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on GLUE, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 61.6 indicates that GLUE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 52.76 indicates that GLUE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 51.47 indicates that GLUE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 36.75 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 44.61 indicates that GLUE is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term GLUE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Monte Rosa Therapeutics Inc financial reports and earnings history, Monte Rosa Therapeutics Inc (GLUE) stock could reach $3.6398 by 2030, $67.31 by 2040 and $44.11 by 2050. See the projected annual prices until 2050 of the Monte Rosa Therapeutics Inc stock below:
- Monte Rosa Therapeutics Inc (GLUE) is expected to reach an average price of $28.03 in 2035, with a high prediction of $28.67 and a low estimate of $28.24. This indicates an $207.64% rise from the last recorded price of $9.11.
- Monte Rosa Therapeutics Inc (GLUE) stock is projected to chart a bullish course in 2040, with an average price target of $66.75, representing an $632.74% surge from its current level. The forecast ranges from a conservative $67.35 to a sky-high $67.31.
- Our analysts predict Monte Rosa Therapeutics Inc (GLUE) to jump 1,242% by 2045, soaring from $120.52 to an average price of $122.26, potentially reaching $119.08. While $120.52 is the low estimate, the potential upside is significant.
- Monte Rosa Therapeutics Inc (GLUE) stock is expected to climb by 2050, reaching an average of $40.32, a $342.58% jump from its current level. However, a wide range of estimates exists, with high and low targets of $44.11 and $41.76, respectively, highlighting the market's uncertainty.
Monte Rosa Therapeutics Inc Stock (GLUE) Year by Year Forecast
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2024
Our forecast for GLUE stock price in 2024 now indicates an average price target of $4.4788 with a high forecast of $8.84 and a low forecast of $0.1177. The average prediction reflects an decrease of -50.84% from the last recorded price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2024 | $8.0087 | $5.7152 | $7.4587 | -12.09% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2025
Monte Rosa Therapeutics Inc Stock (GLUE) is expected to reach an average price of $5.5348 in 2025, with a high prediction of $7.8199 and a low estimate of $3.2497. This indicates an -39.24% fall from the last recorded price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $5.3746 | $8.5049 | $7.8199 | -41.00% |
| February, 2025 | $4.9693 | $5.4681 | $5.2869 | -45.45% |
| March, 2025 | $4.794 | $5.5104 | $4.8728 | -47.38% |
| April, 2025 | $5.2698 | $6.1251 | $5.6786 | -42.15% |
| May, 2025 | $6.6445 | $6.6645 | $6.0122 | -27.06% |
| June, 2025 | $4.3392 | $5.0392 | $5.6766 | -52.37% |
| July, 2025 | $4.5651 | $4.3927 | $4.1315 | -49.89% |
| August, 2025 | $4.7098 | $4.2774 | $3.5298 | -48.30% |
| September, 2025 | $4.9845 | $5.0921 | $4.5509 | -45.29% |
| October, 2025 | $4.8603 | $5.008 | $4.6703 | -46.65% |
| November, 2025 | $5.355 | $5.4338 | $5.2927 | -41.22% |
| December, 2025 | $4.0209 | $3.2497 | $3.9162 | -55.86% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2026
The predicted value for Monte Rosa Therapeutics Inc (GLUE) in 2026 is set at an average of $2.5373. Estimates vary from a peak of $4.9632 to a trough of $0.1114, indicating an -72.15% surge from the present price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $4.7956 | $5.112 | $4.9632 | -47.36% |
| February, 2026 | $2.5203 | $2.8003 | $4.4167 | -72.34% |
| March, 2026 | $2.8349 | $3.2849 | $2.6449 | -68.88% |
| April, 2026 | $2.1208 | $2.2308 | $2.7761 | -76.72% |
| May, 2026 | $2.7855 | $2.4932 | $2.2855 | -69.42% |
| June, 2026 | $2.3902 | $2.5502 | $2.3279 | -73.76% |
| July, 2026 | $5.1661 | $2.4814 | $2.9549 | -43.29% |
| August, 2026 | $4.3008 | $4.4196 | $4.9372 | -52.79% |
| September, 2026 | $2.6866 | $4.0666 | $3.9554 | -70.51% |
| October, 2026 | $1.0963 | $1.1513 | $1.6878 | -87.97% |
| November, 2026 | $0.931 | $1.0533 | $1.6875 | -89.78% |
| December, 2026 | $0.5981 | $0.1114 | $1.4681 | -93.43% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Monte Rosa Therapeutics Inc (GLUE) is $11.92, with a high forecast of $23.83 and a low forecast of $0.0158. This indicates an +30.88% increase from the last price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.3734 | $0.0158 | $2.4334 | -73.95% |
| February, 2027 | $0.9087 | $0.6018 | $3.6023 | -90.02% |
| March, 2027 | $13.35 | $0.2676 | $11.82 | +46.57% |
| April, 2027 | $21.47 | $19.05 | $17.77 | +135.69% |
| May, 2027 | $16.54 | $18.35 | $19.04 | +81.57% |
| June, 2027 | $23.31 | $21.93 | $23.38 | +155.90% |
| July, 2027 | $20.10 | $22.80 | $21.81 | +120.66% |
| August, 2027 | $20.42 | $20.94 | $19.55 | +124.17% |
| September, 2027 | $19.73 | $19.92 | $20.30 | +116.61% |
| October, 2027 | $24.42 | $20.91 | $21.12 | +168.09% |
| November, 2027 | $24.13 | $24.51 | $23.83 | +164.90% |
| December, 2027 | $20.72 | $21.14 | $23.47 | +127.48% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2028
In 2028, Monte Rosa Therapeutics Inc (GLUE) is projected to reach an average price of $17.18, with a high projection of $20.14 and a low estimate of $14.22. This indicates an +88.60% rise from the last price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $20.97 | $20.63 | $19.02 | +130.22% |
| February, 2028 | $20.64 | $20.77 | $19.80 | +126.59% |
| March, 2028 | $20.97 | $21.01 | $20.14 | +130.23% |
| April, 2028 | $19.69 | $20.35 | $19.51 | +116.18% |
| May, 2028 | $17.30 | $17.64 | $18.50 | +89.85% |
| June, 2028 | $17.11 | $17.12 | $17.08 | +87.87% |
| July, 2028 | $16.94 | $17.24 | $17.10 | +86.00% |
| August, 2028 | $15.71 | $16.97 | $16.71 | +72.40% |
| September, 2028 | $17.05 | $16.92 | $16.86 | +87.11% |
| October, 2028 | $15.59 | $15.83 | $16.53 | +71.18% |
| November, 2028 | $16.81 | $14.22 | $15.64 | +84.48% |
| December, 2028 | $14.36 | $14.89 | $15.22 | +57.58% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2029
The 2029 price forecast for Monte Rosa Therapeutics Inc Stock (GLUE) is $8.333 on average, with a high prediction of $12.87 and a low estimate of $3.7978. This represents an -8.53% decrease from the previous price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $12.77 | $12.88 | $12.87 | +40.15% |
| February, 2029 | $11.76 | $11.91 | $12.36 | +29.06% |
| March, 2029 | $11.30 | $11.42 | $11.41 | +24.00% |
| April, 2029 | $11.00 | $11.28 | $11.08 | +20.70% |
| May, 2029 | $11.14 | $10.78 | $10.95 | +22.26% |
| June, 2029 | $12.02 | $11.46 | $12.74 | +31.91% |
| July, 2029 | $11.66 | $11.68 | $11.40 | +27.95% |
| August, 2029 | $7.8979 | $8.8979 | $11.07 | -13.30% |
| September, 2029 | $7.7973 | $7.655 | $7.0403 | -14.41% |
| October, 2029 | $5.899 | $7.2793 | $6.9467 | -35.25% |
| November, 2029 | $4.7784 | $5.0661 | $5.6756 | -47.55% |
| December, 2029 | $3.2078 | $3.7978 | $3.9408 | -64.79% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2030
Monte Rosa Therapeutics Inc Stock (GLUE) is expected to reach an average price of $22.34 in 2030, with a high forecast of $41.47 and a low forecast of $3.2102. This signifies an +145.20% surge from the last price of $9.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.425 | $3.2102 | $3.6398 | -62.40% |
| February, 2030 | $36.67 | $35.00 | $36.37 | +302.53% |
| March, 2030 | $37.49 | $39.46 | $37.82 | +311.58% |
| April, 2030 | $39.85 | $36.83 | $36.69 | +337.42% |
| May, 2030 | $40.32 | $40.83 | $41.47 | +342.55% |
| June, 2030 | $39.14 | $38.44 | $38.11 | +329.64% |
| July, 2030 | $35.98 | $36.82 | $37.40 | +294.93% |
| August, 2030 | $38.61 | $37.51 | $36.07 | +323.84% |
| September, 2030 | $40.23 | $38.53 | $39.68 | +341.56% |
| October, 2030 | $36.60 | $40.37 | $39.84 | +301.80% |
| November, 2030 | $35.41 | $36.09 | $36.12 | +288.67% |
| December, 2030 | $34.44 | $35.75 | $34.72 | +278.07% |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):